(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Zendesk, Chimerix, and Royal Caribbean Cruises.

Rank Financial Asset Price Change Updated (EST)
1 Zendesk (ZEN) 74.07 27.83% 2022-06-24 14:53:29
2 Chimerix (CMRX) 2.13 17.09% 2022-06-24 13:13:06
3 Royal Caribbean Cruises (RCL) 41.74 15.72% 2022-06-24 14:58:50
4 Norwegian Cruise Line (NCLH) 13.23 15.47% 2022-06-24 14:58:39
5 Smith & Wesson (SWBI) 16.58 15.42% 2022-06-24 14:51:03
6 AVEO Pharmaceuticals (AVEO) 6.00 14.94% 2022-06-23 19:06:10
7 Cadiz (CDZI) 2.57 14.22% 2022-06-24 07:41:15
8 U.S. Gold Corp (USAU) 4.32 13.68% 2022-06-24 14:51:39
9 BeiGene (BGNE) 176.07 12.72% 2022-06-24 14:48:12
10 Caesars Entertainment (CZR) 44.43 12.42% 2022-06-24 14:57:01

The three most active and biggest losers today are Century Aluminum Company, DMC Global, and LendingTree.

Rank Financial Asset Price Change Updated (EST)
1 Century Aluminum Company (CENX) 7.11 -16.74% 2022-06-24 07:47:14
2 DMC Global (BOOM) 17.20 -9.76% 2022-06-24 01:08:05
3 LendingTree (TREE) 49.63 -9.55% 2022-06-24 14:46:44
4 Broadway Financial Corporation (BYFC) 1.10 -9.09% 2022-06-24 03:10:05
5 Sorrento Therapeutics (SRNE) 2.10 -8.11% 2022-06-24 14:29:48
6 ProShares UltraShort Nasdaq Biotechnology (BIS) 26.59 -7.74% 2022-06-23 22:43:14
7 Carver Bancorp (CARV) 6.17 -6.8% 2022-06-24 04:41:16
8 Benefitfocus (BNFT) 8.08 -5.83% 2022-06-23 23:49:13
9 Abraxas Petroleum Corporation (AXAS) 1.61 -4.73% 2022-06-23 19:09:06
10 bluebird bio (BLUE) 4.28 -4.04% 2022-06-23 23:15:12

Most Active Winners today

1. Zendesk (ZEN) – 27.83%

Zendesk, Inc. is a software company that develops software for companies in North America, Latin America, Europe, Europe, Asia Pacific, Africa, Australia, Middle East, Africa, Australia, Middle East, Africa, Australia,, and Latin America. Zendesk Support is the company’s flagship product. It allows customers to track, prioritize, and solve support issues across multiple channels. Zendesk Chat is a chat service that allows customers to communicate with each other via mobile, web, or application devices. Zendesk Talk can also be used to manage customer support tickets. Zendesk Guide provides knowledge to help agents and customers. Zendesk Sell (sales customer relationship management) software solution for increasing productivity, pipeline visibility, process transparency, and sales team productivity. Zendesk Explore offers analytics to assist organizations in measuring and improving customer experiences. It also offers Zendesk Sunshine (a CRM platform); Sunshine Conversations (a messaging platform solution); Zendesk Embeddables (which allow developers embed support, chat and guide experiences on mobile and Web applications; as well as Zendesk platform interfaces and apps. Zendesk, Inc. is a strategic partner of Tata Consultancy Services in order to offer enterprise-grade CRM solutions for businesses. It was established in 2007, and has its headquarters in San Francisco, California.

NYSE ended the session with Zendesk jumping 27.83% to $74.07 on Friday, after five consecutive sessions in a row of gains. NYSE jumped 2.84% to $14,811.55, following the last session’s upward trend on what was an all-around positive trend exchanging session today.

Volume

Today’s last reported volume for Zendesk is 40499700 which is 1492.72% above its average volume of 2542800.

Zendesk’s last close was $57.95, 62.23% below its 52-week high of $153.43.

News about Zendesk today

  • Zendesk stock soars after $10 billion buyout deal confirmed at a 34% premium. According to today’s article on MarketWatch, "Shares of Zendesk Inc. soared 29.5% in premarket trading Friday, after the customer experience platform company confirmed a deal to be acquired by an investor group that includes Permira and Hellman & Friedman in an all-cash deal valued at about $10.2 billion. ", "Under terms of the deal, the Permira and H&F will pay $77.50 for each Zendesk share outstanding, which represents a 33.7% premium to Thursday’s closing price of $57.95. "

Zendesk’s Revenue

Year-on-year quarterly revenue growth grew by 30.3%, now sitting on 1.43B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Zendesk’s stock is considered to be oversold (<=20).

Zendesk’s Stock Yearly Top and Bottom Value

Zendesk’s stock is valued at $74.07 at 17:32 EST, way under its 52-week high of $153.43 and way higher than its 52-week low of $54.16.

Zendesk’s Moving Average

Zendesk’s worth is way under its 50-day moving average of $101.47 and way under its 200-day moving average of $107.94.

More news about Zendesk.

2. Chimerix (CMRX) – 17.09%

Chimerix, Inc. is a biopharmaceutical company at the development stage. It focuses its efforts on improving the lives of cancer patients and others with serious illnesses. The company’s clinical-stage programs include dociparstat salt (DSTAT), an antiviral medication candidate, and brincidofovir [BCV], which is being developed as a medical countermeasure to smallpox. ONC201 also includes a program that can potentially treat tumors harboring the H3K27M mutation in patients with diffuse midline and recurrent glioma. Biomedical Advanced research and development Authority has licensed the company to develop brincidofovir to treat smallpox. Cantex Pharmaceuticals, Inc. will develop and market a glycosaminoglycan compounds. SymBio Pharmaceuticals will develop, manufacture, commercialize and sell BCV for various human indications. Chimerix, Inc., was established in 2000. It is located in Durham, North Carolina.

NASDAQ ended the session with Chimerix rising 17.09% to $2.13 on Friday while NASDAQ jumped 3.34% to $11,607.62.

Volume

Today’s last reported volume for Chimerix is 20729500 which is 472.88% above its average volume of 3618460.

Chimerix’s last close was $1.82, 79.27% under its 52-week high of $8.78.

Chimerix’s Sales

Chimerix’s sales growth is a negative 95.8% for the present quarter and 3662.5% for the next. The company’s growth estimates for the present quarter is a negative 14.3% and positive 1200% for the next.

Chimerix’s Revenue

Year-on-year quarterly revenue growth declined by 99%, now sitting on 559k for the twelve trailing months.

Chimerix’s Stock Yearly Top and Bottom Value

Chimerix’s stock is valued at $2.13 at 17:32 EST, way below its 52-week high of $8.78 and way higher than its 52-week low of $1.27.

Chimerix’s Moving Average

Chimerix’s value is way below its 50-day moving average of $3.07 and way below its 200-day moving average of $5.15.

More news about Chimerix.

3. Royal Caribbean Cruises (RCL) – 15.72%

Royal Caribbean Group is a cruise operator. It operates under several brands, including Celebrity Cruises International, Silversea Cruises and Azamara Club Cruises. Royal Caribbean International offers cruises to destinations around the world, such as Alaska, Asia and Australia, Bermuda, Canada. Europe, Canada, The Caribbean, Europe, Panama Canal, New Zealand, Canada, New Zealand, Canada, Europe, Asia, Australia and Bermuda. Cruise lengths range from 2-19 nights. Celebrity Cruises offers cruises to many destinations such as Alaska and Asia, Australia Bermuda, Canada, Europe, South America, Canada, South America, Europe, South America, Canada, New Zealand, South America, Europe, The Galapagos Islands Islands, Hawaii, India, New Zealand and the Panama Canal. Cruise lengths range from 2 to 19 night. Azamara Club Cruises offers cruises to Asia/New Zealand and Northern and Western Europe as well as South America. The cruises last from 3 to 26 night. Silversea Cruises offers itineraries that take you to the Galapagos Islands and Antarctica. Cruise lengths range from 6 to 25 night. The company had 17 ships in order and operated 61 vessels as of December 31, 2019. The company used to be known as Royal Caribbean Cruises Ltd. Royal Caribbean Group, which was established in 1968 in Miami, Florida.

NYSE ended the session with Royal Caribbean Cruises rising 15.72% to $41.74 on Friday, after five sequential sessions in a row of losses. NYSE jumped 2.84% to $14,811.55, following the last session’s upward trend on what was an all-around up trend exchanging session today.

Volume

Today’s last reported volume for Royal Caribbean Cruises is 11479100 which is 173.37% above its average volume of 4199040.

Royal Caribbean Cruises’s last close was $36.07, 63.65% under its 52-week high of $99.24.

Royal Caribbean Cruises’s Sales

Royal Caribbean Cruises’s sales growth is a negative 1930.2% for the ongoing quarter and 3097.1% for the next. The company’s growth estimates for the ongoing quarter and the next is 25.4% and 33.9%, respectively.

Royal Caribbean Cruises’s Revenue

Year-on-year quarterly revenue growth declined by 97.9%, now sitting on 218.07M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Royal Caribbean Cruises’s stock is considered to be overbought (>=80).

Royal Caribbean Cruises’s Stock Yearly Top and Bottom Value

Royal Caribbean Cruises’s stock is valued at $41.74 at 17:32 EST, way below its 52-week low of $64.20.

Royal Caribbean Cruises’s Moving Average

Royal Caribbean Cruises’s value is way below its 50-day moving average of $82.92 and way under its 200-day moving average of $84.22.

More news about Royal Caribbean Cruises.

4. Norwegian Cruise Line (NCLH) – 15.47%

Norwegian Cruise Line Holdings Ltd. and its subsidiaries operate as a cruise operator in North America, Europe. Asia-Pacific. It operates three brands: Oceania Cruises and Regent Seven Seas Cruises. The company offers cruise itineraries that range from just a few days up to over 180 days, visiting various destinations, such as the Mediterranean, Russia, Alaska, Canada, New England, India, Tahiti, South Pacific, Australia, New Zealand, Africa and South America. The company owned 28 vessels with approximately 59.150 berths as of February 20, 2020. The company distributes products via international travel advisor and retail/travel advisor. It also offers onboard sales channels for cruises, meetings, incentive programs, charters, and other distribution methods. It was established in 1966 in Miami and has its headquarters in Florida.

NASDAQ ended the session with Norwegian Cruise Line rising 15.47% to $13.23 on Friday, after two sequential sessions in a row of losses. NASDAQ rose 3.34% to $11,607.62, following the last session’s upward trend on what was a very positive trend exchanging session today.

Volume

Today’s last reported volume for Norwegian Cruise Line is 31065700 which is 50.54% above its average volume of 20635300.

Norwegian Cruise Line’s last close was $11.46, 66.24% below its 52-week high of $33.95.

Norwegian Cruise Line’s Sales

Norwegian Cruise Line’s sales growth is 29714.3% for the current quarter and 820.7% for the next. The company’s growth estimates for the ongoing quarter and the next is 64.8% and 118%, respectively.

Norwegian Cruise Line’s Revenue

Year-on-year quarterly revenue growth grew by 4988.6%, now sitting on 647.99M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Norwegian Cruise Line’s stock is considered to be overbought (>=80).

Norwegian Cruise Line’s Stock Yearly Top and Bottom Value

Norwegian Cruise Line’s stock is valued at $13.23 at 17:32 EST, way under its 52-week high of $33.95 and above its 52-week low of $13.00.

Norwegian Cruise Line’s Moving Average

Norwegian Cruise Line’s worth is way below its 50-day moving average of $18.76 and way below its 200-day moving average of $21.89.

More news about Norwegian Cruise Line.

5. Smith & Wesson (SWBI) – 15.42%

Smith & Wesson Brands, Inc. manufactures, sells, and designs firearms around the world. It offers firearms products such as pistols, revolvers, modern sporting rifles and bolt-action rifles. Handcuffs are also available. The company also offers manufacturing services that include heat treating, rapid prototyping and tooling. It can also finish, plating and machining parts bought through third-party sellers. It sells products to hunters, gun collectors, competitors, shooters and sportsmen as well as individuals who are looking for home or personal security, police, military personnel, security officers and other law enforcement agencies. Smith & Wesson Brands, Inc. sells its products to independent dealers, retailers, retails, direct to consumers, print, broadcast, digital, social media, and in-store retail merchandising. In June 2020, Smith & Wesson Brands, Inc. was renamed to American Outdoor Brands Corporation. Smith & Wesson Brands, Inc. is a Massachusetts-based company that was established in 1852.

NASDAQ ended the session with Smith & Wesson rising 15.42% to $16.58 on Friday while NASDAQ rose 3.34% to $11,607.62.

Volume

Today’s last reported volume for Smith & Wesson is 4431060 which is 428.98% above its average volume of 837646.

Smith & Wesson’s last close was $14.36, 63.75% under its 52-week high of $39.61.

The company’s growth estimates for the current quarter is 41.9% and a drop 6.3% for the next.

Smith & Wesson’s Revenue

Year-on-year quarterly revenue growth grew by 19.5%, now sitting on 1.1B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Smith & Wesson’s stock is considered to be overbought (>=80).

Smith & Wesson’s Stock Yearly Top and Bottom Value

Smith & Wesson’s stock is valued at $16.58 at 17:32 EST, way below its 52-week high of $39.61 and way above its 52-week low of $14.50.

Smith & Wesson’s Moving Average

Smith & Wesson’s worth is way below its 50-day moving average of $21.46 and way below its 200-day moving average of $21.69.

More news about Smith & Wesson.

6. AVEO Pharmaceuticals (AVEO) – 14.94%

AVEO Pharmaceuticals, Inc. is a biopharmaceutical firm that focuses on the development and commercialization of medicines for patients with cancer. FOTIVDA is the company’s lead product. It is an oral once daily, vascular growth factor receptor activator tyrosinekinase inhibitor that can be used to treat renal cell carcinoma (RCC). A Phase II clinical trial was also conducted by the company using tivozanib and Opdivo (nivolumab), for treatment of RCC. Ficlatuzumab is also being developed by the company. This is a humanized immunoglobulin G1 monoclonal monoclonal anti-hepatocyte growth factors (IgG1) that has a strong potential to treat RCC. It is currently in a Phase 2 clinical trial. The preclinical stage product of the company includes AV-353, which targets Notch 3 pathways. AVEO Pharmaceuticals, Inc. is a member of the following collaborations: CANbridge Life Sciences Ltd., EUSA Pharma (UK Limited), Novartis International Pharmaceutical Ltd., Biodesix, Inc., St. Vincent’s Hospital Sydney Limited, Biogen Idec International GmbH, Kyowa Kirin Co., Ltd., AstraZeneca PLC, and Bristol Myers Squibb. The former name of the company was GenPath Pharmaceuticals, Inc., but it changed its name to AVEO Pharmaceuticals, Inc. on March 5, 2005. AVEO Pharmaceuticals, Inc. is a Massachusetts-based company that was founded in 2001.

NASDAQ ended the session with AVEO Pharmaceuticals rising 14.94% to $6.00 on Friday while NASDAQ jumped 3.34% to $11,607.62.

Volume

Today’s last reported volume for AVEO Pharmaceuticals is 862438 which is 322.14% above its average volume of 204300.

AVEO Pharmaceuticals’s last close was $6.00, 20.53% below its 52-week high of $7.55.

The company’s growth estimates for the current quarter is 27.5% and a drop 6.7% for the next.

AVEO Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 989.6%, now sitting on 61.3M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

AVEO Pharmaceuticals’s stock is considered to be oversold (<=20).

AVEO Pharmaceuticals’s Stock Yearly Top and Bottom Value

AVEO Pharmaceuticals’s stock is valued at $6.00 at 17:32 EST, way below its 52-week high of $7.55 and way higher than its 52-week low of $3.06.

AVEO Pharmaceuticals’s Moving Average

AVEO Pharmaceuticals’s value is way higher than its 50-day moving average of $4.54 and way higher than its 200-day moving average of $5.16.

More news about AVEO Pharmaceuticals.

7. Cadiz (CDZI) – 14.22%

Cadiz Inc. is a United States-based natural resource development company. The company is involved in water resource development and agriculture in San Bernardino County. It owns 35,000 acres in eastern San Bernardino County’s Cadiz, Fenner and eastern Mojave Desert portions. The company also cultivates lemons and produces vegetables and grain crops in spring and autumn. Cadiz Inc. is located in Los Angeles.

NASDAQ ended the session with Cadiz rising 14.22% to $2.57 on Friday while NASDAQ jumped 3.34% to $11,607.62.

Volume

Today’s last reported volume for Cadiz is 537412 which is 90.43% above its average volume of 282200.

Cadiz’s last close was $2.57, 82.51% below its 52-week high of $14.69.

Cadiz’s Revenue

Year-on-year quarterly revenue growth grew by 1.4%, now sitting on 564k for the twelve trailing months.

Cadiz’s Stock Yearly Top and Bottom Value

Cadiz’s stock is valued at $2.57 at 17:32 EST, way under its 52-week high of $14.69 and way above its 52-week low of $1.66.

Cadiz’s Moving Average

Cadiz’s worth is way higher than its 50-day moving average of $2.03 and way below its 200-day moving average of $3.81.

More news about Cadiz.

8. U.S. Gold Corp (USAU) – 13.68%

NASDAQ ended the session with U.S. Gold Corp jumping 13.68% to $4.32 on Friday, after five sequential sessions in a row of losses. NASDAQ rose 3.34% to $11,607.62, following the last session’s upward trend on what was a very up trend trading session today.

Volume

Today’s last reported volume for U.S. Gold Corp is 126482 which is 142.86% above its average volume of 52079.

U.S. Gold Corp’s last close was $3.80, 78.16% under its 52-week high of $17.40.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

U.S. Gold Corp’s stock is considered to be overbought (>=80).

U.S. Gold Corp’s Stock Yearly Top and Bottom Value

U.S. Gold Corp’s stock is valued at $4.32 at 17:32 EST, way under its 52-week low of $8.50.

U.S. Gold Corp’s Moving Average

U.S. Gold Corp’s value is way below its 50-day moving average of $10.13 and way under its 200-day moving average of $10.50.

More news about U.S. Gold Corp.

9. BeiGene (BGNE) – 12.72%

BeiGene, Ltd. is a biotech company in commercial stage. It develops and markets immuno-oncology and molecularly targeted cancer therapies. BRUKINSA is used to treat R/R classic Hodgkin’s lymphoma. Tislelizumab is used to treat R/R human lymphoma. REVLIMID is used to treat multiple myeloma. KYPROLIS can be used to treat multiple myeloma. BLINCYTO treats acute lymphocytic encephalopathy. SYLVANT, which treat idiopathic multicentric Castleman disease. QARZIBA, to deal with neuroblastoma. Zanubrutinib is a BTK inhibitor that treats various lymphomas. Tislelizumab is an anti-PD-1 anti-cancer antibody to treat many solid and hematological tumors. Pamiparib to treat multiple myeloma; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and to treatment of solid tumors. BGB – A333 is a PD-1 inhibitor that can be used to treat different solid tumors. BGB – A1217 is a TIGIT inhibitor that can also treat certain solid tumors. BGB – 11417 is a small molecule Bcl-2 inhibiter to help treat advanced B-cell malignancies. BGB – A445, an OX40 agonist anti-tumor antibody, will also be available in clinical stages. Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., BioAtla, Inc., Zymeworks, Inc., Atreca Inc., IGM Biosciences, Inc., and Hutchison China MediTech Limited have collaborated with the company. BeiGene, Ltd., was established in Beijing, People’s Republic of China in 2010.

NASDAQ ended the session with BeiGene rising 12.72% to $176.07 on Friday, after three consecutive sessions in a row of gains. NASDAQ rose 3.34% to $11,607.62, following the last session’s upward trend on what was a very positive trend exchanging session today.

Volume

Today’s last reported volume for BeiGene is 428618 which is 51.18% above its average volume of 283503.

BeiGene’s last close was $156.20, 63.38% under its 52-week high of $426.56.

BeiGene’s Sales

BeiGene’s sales growth is 226.8% for the current quarter and a decline by 57.9% for the next. The company’s growth estimates for the current quarter and the next is a negative 1.7% and a negative 788.4%, respectively.

BeiGene’s Revenue

Year-on-year quarterly revenue growth grew by 113.8%, now sitting on 1.18B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

BeiGene’s stock is considered to be oversold (<=20).

BeiGene’s Stock Yearly Top and Bottom Value

BeiGene’s stock is valued at $176.07 at 17:32 EST, way under its 52-week high of $426.56 and way above its 52-week low of $118.18.

BeiGene’s Moving Average

BeiGene’s worth is way higher than its 50-day moving average of $150.90 and way under its 200-day moving average of $252.61.

More news about BeiGene.

10. Caesars Entertainment (CZR) – 12.42%

Caesars Entertainment, Inc. is a US casino-entertainment firm. It operates resorts under the Caesars Entertainment, Harrah’s and Horseshoe brand names. The company offers a variety of amenities, unique destinations and gaming services. It was established in Reno in Nevada in 1937.

NASDAQ ended the session with Caesars Entertainment rising 12.42% to $44.43 on Friday while NASDAQ jumped 3.34% to $11,607.62.

Volume

Today’s last reported volume for Caesars Entertainment is 4699610 which is 29.04% above its average volume of 3641770.

Caesars Entertainment’s last close was $39.52, 67.01% below its 52-week high of $119.81.

Caesars Entertainment’s Sales

Caesars Entertainment’s sales growth is 9.8% for the ongoing quarter and 7% for the next. The company’s growth estimates for the present quarter is a negative 88.2% and positive 110% for the next.

Caesars Entertainment’s Revenue

Year-on-year quarterly revenue growth grew by 63.5%, now sitting on 9.57B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Caesars Entertainment’s stock is considered to be overbought (>=80).

Caesars Entertainment’s Stock Yearly Top and Bottom Value

Caesars Entertainment’s stock is valued at $44.43 at 17:32 EST, way under its 52-week high of $119.81 and way above its 52-week low of $37.03.

Caesars Entertainment’s Moving Average

Caesars Entertainment’s value is way below its 50-day moving average of $56.34 and way under its 200-day moving average of $83.76.

More news about Caesars Entertainment.

Most Active Losers Today

1. Century Aluminum Company (CENX) – -16.74%

Century Aluminum Company and its subsidiaries produce standard-grade primary aluminum products in America and Iceland. It was founded in 1981 in Chicago, Illinois.

NASDAQ ended the session with Century Aluminum Company dropping 16.74% to $7.11 on Friday, after two successive sessions in a row of losses. NASDAQ jumped 3.34% to $11,607.62, following the last session’s upward trend on what was a very positive trend exchanging session today.

Volume

Today’s last reported volume for Century Aluminum Company is 5543830 which is 129.05% above its average volume of 2420260.

Century Aluminum Company’s last close was $7.11, 76.58% below its 52-week high of $30.36.

The company’s growth estimates for the current quarter and the next is 318.5% and 1733.3%, respectively.

Century Aluminum Company’s Revenue

Year-on-year quarterly revenue growth grew by 69.7%, now sitting on 2.52B for the twelve trailing months.

Century Aluminum Company’s Stock Yearly Top and Bottom Value

Century Aluminum Company’s stock is valued at $7.11 at 17:32 EST, way below its 52-week high of $30.36 and above its 52-week low of $6.93.

Century Aluminum Company’s Moving Average

Century Aluminum Company’s value is way under its 50-day moving average of $14.77 and way under its 200-day moving average of $16.95.

More news about Century Aluminum Company.

2. DMC Global (BOOM) – -9.76%

DMC Global Inc. offers a range of products and services for global markets in the infrastructure, energy, and industrial sectors. It operates two divisions, DynaEnergetics and NobelClad. The company’s NobelClad division produces and markets explosion-welded, clad metal plates that are used in construction of high temperature, corrosion-resistant pressure vessels and heat exchangers. These can be used for hydrometallurgy and aluminum production as well as shipbuilding and power generation. It sells products via direct sales, program managers and independent sales reps. The company’s DynaEnergetics division designs, produces, markets and sells perforating system, which includes initiation systems and detonating cords. The company sells products via distributors and independent sales reps. The company used to be called Dynamic Materials Corp., but changed its name in November 2016 to DMC Global Inc. DMC Global Inc. was established in 1965. It is located in Broomfield Colorado.

NASDAQ ended the session with DMC Global dropping 9.76% to $17.20 on Friday while NASDAQ jumped 3.34% to $11,607.62.

Volume

Today’s last reported volume for DMC Global is 217647 which is 52.83% above its average volume of 142403.

DMC Global’s last close was $17.20, 71.21% below its 52-week high of $59.74.

The company’s growth estimates for the ongoing quarter is a negative 160% and positive 1300% for the next.

DMC Global’s Revenue

Year-on-year quarterly revenue growth grew by 149.2%, now sitting on 343.17M for the twelve trailing months.

DMC Global’s Stock Yearly Top and Bottom Value

DMC Global’s stock is valued at $17.20 at 17:32 EST, way under its 52-week high of $59.74 and higher than its 52-week low of $16.67.

DMC Global’s Moving Average

DMC Global’s worth is way under its 50-day moving average of $24.42 and way below its 200-day moving average of $34.41.

More news about DMC Global.

3. LendingTree (TREE) – -9.55%

LendingTree, Inc. operates an online platform for consumers in the United States through LendingTree, LLC, its subsidiary. The company operates in three segments: Home, Consumer, Insurance. Its Home segment provides purchase, refinance, reverse, and equity mortgage loans, lines of credit, and brokerage services. The Consumer segment offers credit cards, personal, small-business, student and auto loans, deposit accounts, as well as other credit products such credit repair services and debt settlement. Its Insurance segment provides information and tools as well access to quotes products. This includes home and auto. Consumers are then matched up with lead aggregators in order to receive insurance offers. The company also owns CompareCards which is an online resource for side-by-side comparison shopping for credit cards; SimpleTuition which offers student loans marketing platforms; MagnifyMoney that provides editorial content and expert commentary; SnapCap that connects businesses owners and lenders; ValuePenguin that gives consumers an objective analysis and QuoteWizard.com that allows for comparison of insurance prices; Student Loan Hero that helps student loan borrowers to manage student loan debt. In January 2015, the company, formerly Tree.com, Inc., was changed to LendingTree, Inc. LendingTree, Inc. is located in Charlotte, North Carolina.

NASDAQ ended the session with LendingTree falling 9.55% to $49.63 on Friday while NASDAQ rose 3.34% to $11,607.62.

Volume

Today’s last reported volume for LendingTree is 773658 which is 261.3% above its average volume of 214127.

LendingTree’s last close was $54.87, 76.02% under its 52-week high of $228.81.

LendingTree’s Sales

LendingTree’s sales growth is 6.5% for the current quarter and 5.1% for the next. The company’s growth estimates for the ongoing quarter is a negative 15.8% and positive 10.7% for the next.

LendingTree’s Revenue

Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 1.1B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

LendingTree’s stock is considered to be oversold (<=20).

LendingTree’s Stock Yearly Top and Bottom Value

LendingTree’s stock is valued at $49.63 at 17:32 EST, way under its 52-week high of $228.81 and above its 52-week low of $48.32.

LendingTree’s Moving Average

LendingTree’s value is way below its 50-day moving average of $74.17 and way below its 200-day moving average of $115.65.

Previous days news about LendingTree

  • Lendingtree stock falls after decline in mortgage activity leads to guidance cut. According to MarketWatch on Thursday, 23 June, "We have seen the most significant impact in our Home segment as mortgage rates have nearly doubled over the last six months, causing a sharp decline in refinance volumes and more recent pressure on purchase activity." Ziegler also said that LendingTree executives were reviewing the company’s annual guidance, and would provide revised guidance for the year when they present full second-quarter results next month. "

More news about LendingTree.

4. Broadway Financial Corporation (BYFC) – -9.09%

Broadway Financial Corporation is the holding company of City First Bank, National Association. This bank provides various services and products in the United States. You can open a variety of deposits accounts including checking and savings accounts as well as checking, NOW, money market, fixed-term certificates, and certificate deposit. It also offers mortgage loans that are secured by single-family and multi-family homes, commercial real estate and construction loans and business loans. It also invests in securities from federal agencies and residential mortgage-backed security, as well as other investments. Three branches are used to operate the company. Broadway Financial Corporation was established in 1946. It is located in Los Angeles, California.

NASDAQ ended the session with Broadway Financial Corporation sliding 9.09% to $1.10 on Friday while NASDAQ rose 3.34% to $11,607.62.

Volume

Today’s last reported volume for Broadway Financial Corporation is 1771060 which is 451.92% above its average volume of 320887.

Broadway Financial Corporation’s last close was $1.10, 74.3% below its 52-week high of $4.28.

Broadway Financial Corporation’s Revenue

Year-on-year quarterly revenue growth grew by 146.5%, now sitting on 28.35M for the twelve trailing months.

Broadway Financial Corporation’s Stock Yearly Top and Bottom Value

Broadway Financial Corporation’s stock is valued at $1.10 at 17:33 EST, way below its 52-week high of $4.28 and way higher than its 52-week low of $0.88.

Broadway Financial Corporation’s Moving Average

Broadway Financial Corporation’s worth is way below its 50-day moving average of $1.52 and way below its 200-day moving average of $2.20.

More news about Broadway Financial Corporation.

5. Sorrento Therapeutics (SRNE) – -8.11%

Sorrento Therapeutics, Inc., is a biopharma company at clinical stage. It develops treatments for neurodegenerative, autoimmune, and cancer. The company operates in two segments: Sorrento Therapeutics, and Scilex. It offers cancer therapies by using its G-MAB proprietary antibody library and targeted delivery modes. These include CAR-T, dimeric antigen T-cell treatment (CAR-T), and antibody drug conjugates as well as bispecific approaches. Sofusa is a technology to deliver biologics directly into your lymphatic system. The company is also developing anti-CD38 CAR–T therapies for multiple myeloma and amyloidosis. It also develops resiniferatoxin (a non-opioid TRPV1 antagonist neurotoxin) for treatment of osteoarthritis and late-stage cancer; ZTlido (a lidocaine delivery method for postherpetic nerve pain); and ZTido (a lidocaine delivery device for treatment of postherpetic narcolepsy). SEMDEXA is an injectable viscous jelly formulation that the company has been developing. It’s currently in Phase III clinical trials for sciatica. SP-103 is an investigational, non-aqueous, lidocaine-based topical system in clinical development. SmartPharm Therapeutics Inc. is one of its partners in developing a gene-encoded vaccine against COVID-19. Celularity, Inc. initiated Phase I/II clinical studies, which included up to 86 patients. Mount Sinai Health System was involved in the development of COVI-SHIELD, an anti-SARS treatment. It also has a preclinical agreement with Galveston’s University of Texas Medical Branch for testing Sorrento’s COVID-19 therapeutic products candidates. It was established in San Diego in 2006.

NASDAQ ended the session with Sorrento Therapeutics sliding 8.11% to $2.10 on Friday, after four sequential sessions in a row of gains. NASDAQ jumped 3.34% to $11,607.62, following the last session’s upward trend on what was a very positive trend trading session today.

Volume

Today’s last reported volume for Sorrento Therapeutics is 9655590 which is 1.6% below its average volume of 9813310.

Sorrento Therapeutics’s last close was $2.28, 79.4% under its 52-week high of $11.07.

Sorrento Therapeutics’s Sales

Sorrento Therapeutics’s sales growth is 29% for the current quarter and 85.1% for the next. The company’s growth estimates for the present quarter is a negative 1700% and positive 77.2% for the next.

Sorrento Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 13.7%, now sitting on 52.9M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Sorrento Therapeutics’s stock is considered to be oversold (<=20).

Sorrento Therapeutics’s Stock Yearly Top and Bottom Value

Sorrento Therapeutics’s stock is valued at $2.10 at 17:33 EST, way below its 52-week high of $11.07 and way above its 52-week low of $1.15.

Sorrento Therapeutics’s Moving Average

Sorrento Therapeutics’s worth is way above its 50-day moving average of $1.70 and way below its 200-day moving average of $4.40.

More news about Sorrento Therapeutics.

6. ProShares UltraShort Nasdaq Biotechnology (BIS) – -7.74%

NASDAQ ended the session with ProShares UltraShort Nasdaq Biotechnology dropping 7.74% to $26.59 on Friday, after four sequential sessions in a row of losses. NASDAQ jumped 3.34% to $11,607.62, following the last session’s upward trend on what was a very positive trend trading session today.

Volume

Today’s last reported volume for ProShares UltraShort Nasdaq Biotechnology is 29953 which is 33.21% above its average volume of 22485.

More news about ProShares UltraShort Nasdaq Biotechnology.

7. Carver Bancorp (CARV) – -6.8%

Carver Bancorp, Inc. is the holding company of Carver Federal Savings Bank, which is a federally chartered bank providing consumer and commercial banking services to consumers, businesses, as well as governmental and quasi-governmental entities primarily in New York. You can deposit with it a variety of products including time, demand and savings deposits, passbook and statement accounts and certificates, as well as individual retirement accounts. It also offers lending products such as multifamily residential and family residential loans, small-business administration and consumer loans, and business, construction and business loans. It also offers additional consumer and commercial banking services such as debit card, online banking and account opening, bill pay online, telephone banking and check cashing. One administrative office is used by the company, as well as seven branches and four ATMs. Carver Bancorp, Inc., was established in 1948. It is located in New York, New York.

NASDAQ ended the session with Carver Bancorp dropping 6.8% to $6.17 on Friday, after two consecutive sessions in a row of losses. NASDAQ rose 3.34% to $11,607.62, following the last session’s upward trend on what was a very up trend trading session today.

Volume

Today’s last reported volume for Carver Bancorp is 441736 which is 93.07% above its average volume of 228790.

Carver Bancorp’s last close was $6.17, 85.48% under its 52-week high of $42.50.

Carver Bancorp’s Revenue

Year-on-year quarterly revenue growth grew by 33.3%, now sitting on 27.03M for the twelve trailing months.

Carver Bancorp’s Stock Yearly Top and Bottom Value

Carver Bancorp’s stock is valued at $6.17 at 17:33 EST, way under its 52-week high of $42.50 and above its 52-week low of $5.98.

Carver Bancorp’s Moving Average

Carver Bancorp’s value is way below its 50-day moving average of $8.23 and way under its 200-day moving average of $10.28.

More news about Carver Bancorp.

8. Benefitfocus (BNFT) – -5.83%

Benefitfocus, Inc. offers cloud-based technology solutions to manage benefits for American employers. Benefitplace is a cloud-based benefit management platform that facilitates online enrollment and employee communication. Health Insights provides data analysis solutions. ACA Management and Reporting allows employers to monitor ACA compliance. Billing & payments, which synchronizes enrollment and bill information, streamlines the monthly billing process and automates adjustments. COBRA Administration simplifies managing benefits under Consolidated Omnibus Budget Reconciliation Act. Enrollment, which allows carriers to streamline enrollment in all their segments, is a platform that allows them to do so; Billing & Payments provides an electronic invoice presentation and payment system; Exchange bridges the gap between employer and health plan systems. Quoting gives brokers and health plans tools to manage and organize accounts and generate leads. The company’s products are available to brokers: Health Insights, which supports strategic decisions for clients through on-demand analytics for health plans; Benefit Catalog that allows brokers to sell products to clients; as well as benefit consulting support for brokers via benefit advisors. It also offers implementation services for its clients to ensure smooth deployment and efficient utilization of its solutions. Employers can access expanded support services. Company was founded in 2000 in Charleston, South Carolina.

NASDAQ ended the session with Benefitfocus dropping 5.83% to $8.08 on Friday while NASDAQ jumped 3.34% to $11,607.62.

Volume

Today’s last reported volume for Benefitfocus is 233421 which is 78.19% above its average volume of 130993.

Benefitfocus’s last close was $8.08, 45.44% below its 52-week high of $14.81.

Benefitfocus’s Sales

Benefitfocus’s sales growth is a negative 6.6% for the present quarter and a decline by 1.9% for the next. The company’s growth estimates for the ongoing quarter and the next is 16.7% and 52.6%, respectively.

Benefitfocus’s Revenue

Year-on-year quarterly revenue growth declined by 1.5%, now sitting on 263.1M for the twelve trailing months.

Benefitfocus’s Stock Yearly Top and Bottom Value

Benefitfocus’s stock is valued at $8.08 at 17:33 EST, way below its 52-week high of $14.81 and above its 52-week low of $7.63.

Benefitfocus’s Moving Average

Benefitfocus’s value is way below its 50-day moving average of $9.71 and way under its 200-day moving average of $10.56.

More news about Benefitfocus.

9. Abraxas Petroleum Corporation (AXAS) – -4.73%

Abraxas Petroleum Corporation is an independent energy company that focuses on the acquisition, exploration and exploitation of oil and natural gas properties throughout the United States. It operates oil and natural gas assets throughout the Permian/Delaware Basin, Rocky Mountain and Rocky Mountain regions. Its net proven reserves, as of December 31, 2020 were estimated at 16.8 million barrels oil equivalent. It was established in San Antonio in Texas in 1977.

NASDAQ ended the session with Abraxas Petroleum Corporation sliding 4.73% to $1.61 on Friday while NASDAQ rose 3.34% to $11,607.62.

Volume

Today’s last reported volume for Abraxas Petroleum Corporation is 24427 which is 29.39% below its average volume of 34598.

Abraxas Petroleum Corporation’s last close was $1.61, 67.41% under its 52-week high of $4.94.

Abraxas Petroleum Corporation’s Sales

Abraxas Petroleum Corporation’s sales growth is 65.6% for the present quarter and 79.7% for the next.

Abraxas Petroleum Corporation’s Revenue

Year-on-year quarterly revenue growth declined by 26.9%, now sitting on 74.37M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Abraxas Petroleum Corporation’s stock is considered to be overbought (>=80).

Abraxas Petroleum Corporation’s Stock Yearly Top and Bottom Value

Abraxas Petroleum Corporation’s stock is valued at $1.61 at 17:33 EST, way under its 52-week high of $4.94 and way higher than its 52-week low of $0.52.

Abraxas Petroleum Corporation’s Moving Average

Abraxas Petroleum Corporation’s value is way below its 50-day moving average of $1.96 and under its 200-day moving average of $1.64.

More news about Abraxas Petroleum Corporation.

10. bluebird bio (BLUE) – -4.04%

bluebird bio, Inc. is a biotech company that develops, markets, and sells gene therapies to treat severe genetic disorders and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent AY-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. Idecabtagene Vicleucel, and bb21217 are the company’s oncology product candidates. These products can be used to treat multiple myeloma by using chimeric antigen receptor (CAR) T cell product candidates. There are license and collaboration agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone oncology, Inc., Magenta Therapeutics, Inc., University of North Carolina, Fred Hutchinson Cancer Research Center, as well as Bristol-Myers Squibb. bluebird bio, Inc. is a member of a strategic alliance with National Resilience, Inc. for the development, delivery, and research in cell therapies. The original name of the company was Genetix Pharmaceuticals, Inc., but it was renamed bluebird bio, Inc. on September 10, 2010. bluebird bio, Inc. is a Massachusetts-based corporation that was founded in 1992.

NASDAQ ended the session with bluebird bio falling 4.04% to $4.28 on Friday while NASDAQ jumped 3.34% to $11,607.62.

Volume

Today’s last reported volume for bluebird bio is 11077900 which is 100.76% above its average volume of 5517840.

bluebird bio’s last close was $4.28, 79.78% below its 52-week high of $21.17.

bluebird bio’s Sales

bluebird bio’s sales growth is a negative 84.1% for the current quarter and a decline by 96.7% for the next. The company’s growth estimates for the ongoing quarter and the next is 65.9% and 66.8%, respectively.

bluebird bio’s Stock Yearly Top and Bottom Value

bluebird bio’s stock is valued at $4.28 at 17:33 EST, way below its 52-week high of $21.17 and way higher than its 52-week low of $2.87.

bluebird bio’s Moving Average

bluebird bio’s value is way higher than its 50-day moving average of $3.69 and way below its 200-day moving average of $7.92.

More news about bluebird bio.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here